Our study focuses on advanced NSCLC with EGFR mutation treated with first-generation EGFR-TKIs, which is different from most of the studies in the meta-analysis [11,36] that focus on NSCLC treated with chemotherapy, radiotherapy, or surgery and range from early to advanced stages. This evidence concerns the gene EGFR and non-small cell lung carcinoma.